Last reviewed · How we verify
Kisqali — Competitive Intelligence Brief
marketed
Kinase Inhibitor
Cyclin-dependent kinase 4
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Kisqali (LEE011) — Novartis. Kisqali works by blocking a protein called cyclin-dependent kinase 4, which helps cancer cells grow and divide.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Kisqali TARGET | LEE011 | Novartis | marketed | Kinase Inhibitor | Cyclin-dependent kinase 4 | 2017-01-01 |
| Wayrilz | RILZABRUTINIB | Genzyme Corp | marketed | Kinase Inhibitor [EPC] | 2025-01-01 | |
| Romvimza | VIMSELTINIB | Deciphera Pharms | marketed | Kinase Inhibitor [EPC] | 2025-01-01 | |
| Itovebi | INAVOLISIB | Genentech Inc | marketed | Kinase Inhibitor [EPC] | 2025-01-01 | |
| Hernexeos | ZONGERTINIB | Boehringer Ingelheim | marketed | Kinase Inhibitor [EPC] | 2025-01-01 | |
| Ojemda | TOVORAFENIB | Day One Biopharms | marketed | Kinase Inhibitor [EPC] | 2024-01-01 | |
| Itovebi | inavolisib | Pfizer | marketed | Kinase Inhibitor [EPC] | phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA) | 2024-01-01 |
Recent regulatory actions (last 90 days)
- — Hernexeos · FDA · approved · US · Boehringer Ingelheim
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Kisqali · 8324225 · US
- — Kisqali · 9416136 · US
- — Kisqali · 8962630 · US
- — Kisqali · 8685980 · US
- — Kisqali · 8415355 · US
- — Kisqali · 9193732 · US
- — Kisqali · 9868739 · US
- — Kisqali · 10799506 · US
Sponsor landscape (Kinase Inhibitor class)
- Novartis · 5 drugs in this class
- Pfizer · 3 drugs in this class
- Bayer · 2 drugs in this class
- Boehringer Ingelheim · 2 drugs in this class
- Hoffmann-La Roche · 1 drug in this class
- Exelixis Inc · 1 drug in this class
- Novartis Pharm · 1 drug in this class
- Osi Pharms · 1 drug in this class
- Exelixis · 1 drug in this class
- Roche · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Kisqali CI watch — RSS
- Kisqali CI watch — Atom
- Kisqali CI watch — JSON
- Kisqali alone — RSS
- Whole Kinase Inhibitor class — RSS
Cite this brief
Drug Landscape (2026). Kisqali — Competitive Intelligence Brief. https://druglandscape.com/ci/lee011. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab